128 related articles for article (PubMed ID: 12181257)
1. Exacerbation of oxaliplatin neurosensory toxicity following surgery.
Gornet JM; Savier E; Lokiec F; Cvitkovic E; Misset JL; Goldwasser F
Ann Oncol; 2002 Aug; 13(8):1315-8. PubMed ID: 12181257
[TBL] [Abstract][Full Text] [Related]
2. [Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation].
Cournede A; Ries P; Richard K; Guillain A; Dahan L; Grandval P; Pourroy B; Moutardier V; Hardwigsen J; Braguer D; Seitz JF
Gastroenterol Clin Biol; 2005 Apr; 29(4):461-4. PubMed ID: 15864213
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of patients with intestinal cancer. Increased neurotoxicity after oxaliplatin and related liver metastasis].
Junker A; Kretzschmar A; Böhm U; Tannapfel A; Langenbahn D; Pieck AC; Jaehde U
Med Monatsschr Pharm; 2004 Oct; 27(10):349-52. PubMed ID: 15527179
[No Abstract] [Full Text] [Related]
6. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
9. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Chang YY; Lin JK; Jiang JK
Colorectal Dis; 2012 Dec; 14(12):e821. PubMed ID: 22330089
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety profile of oxaliplatin.
Extra JM; Marty M; Brienza S; Misset JL
Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
[TBL] [Abstract][Full Text] [Related]
14. Radiation recall with oxaliplatin: report of a case and a review of the literature.
Chan RT; Au GK; Ho JW; Chu KW
Clin Oncol (R Coll Radiol); 2001; 13(1):55-7. PubMed ID: 11292139
[TBL] [Abstract][Full Text] [Related]
15. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M
Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004
[TBL] [Abstract][Full Text] [Related]
16. Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy.
Christodoulou C; Anastasopoulos D; Visvikis A; Mellou S; Detsi I; Tsiakalos G; Pateli A; Klouvas G; Papadimitriou A; Skarlos DV
Anticancer Drugs; 2004 Nov; 15(10):997-9. PubMed ID: 15514570
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
18. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
[TBL] [Abstract][Full Text] [Related]
19. A case report of oxaliplatin extravasation.
Foo KF; Michael M; Toner G; Zalcberg J
Ann Oncol; 2003 Jun; 14(6):961-2. PubMed ID: 12796037
[No Abstract] [Full Text] [Related]
20. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
